康拓医疗(688314) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥69,917,918.34, representing an increase of 8.16% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥19,935,123.47, reflecting a growth of 2.65% year-over-year[4]. - Total revenue for Q1 2024 reached 84,041,264.22 RMB, an increase from 75,942,249.47 RMB in Q1 2023, representing a growth of approximately 14%[22]. - Net profit for Q1 2024 was 19,621,574.10 RMB, compared to 19,079,127.44 RMB in Q1 2023, showing an increase of about 2.85%[19]. - Operating profit for Q1 2024 was 24,280,898.34 RMB, up from 23,373,219.85 RMB in Q1 2023, reflecting a growth of approximately 3.88%[18]. - Total comprehensive income for Q1 2024 was 19,220,488.16 RMB, compared to 18,884,533.92 RMB in Q1 2023, an increase of about 1.79%[19]. Cash Flow and Assets - The net cash flow from operating activities surged by 142.56%, amounting to ¥33,563,731.94, primarily due to increased cash receipts from sales[4][7]. - Cash flow from operating activities for Q1 2024 was 33,563,731.94 RMB, significantly higher than 13,837,410.61 RMB in Q1 2023, indicating a growth of approximately 142%[22]. - Cash and cash equivalents decreased to ¥308,934,158.47 from ¥375,119,786.33, representing a decline of 17.7%[13]. - The cash and cash equivalents at the end of Q1 2024 were 308,934,158.47 RMB, down from 255,710,751.50 RMB at the end of Q1 2023[24]. - Total assets at the end of the reporting period reached ¥694,867,666.59, up 2.82% from the end of the previous year[5]. - Total assets increased to ¥694,867,666.59 from ¥675,787,403.12, reflecting a growth of 2.4%[15]. Shareholder Information - The equity attributable to shareholders increased by 3.22% to ¥606,075,048.04 compared to the previous year-end[5]. - The equity attributable to shareholders increased to ¥606,075,048.04 from ¥587,184,063.37, an increase of 3.0%[15]. - The total number of ordinary shareholders at the end of the reporting period was 4,721[9]. Expenses and Costs - Research and development expenses totaled ¥4,655,270.57, accounting for 6.66% of operating revenue, which is an increase of 0.47 percentage points[4]. - Research and development expenses increased to 4,655,270.57 RMB in Q1 2024 from 4,000,571.62 RMB in Q1 2023, marking a rise of about 16.38%[18]. - The total operating costs for Q1 2024 were 44,390,295.19 RMB, up from 41,550,307.81 RMB in Q1 2023, indicating an increase of about 6.4%[18]. Investment and Income - The company reported a decrease in investment income, with a loss of 2,201,609.87 RMB in Q1 2024 compared to a gain of 184,060.50 RMB in Q1 2023[18]. - The company received government subsidies amounting to ¥1,130,689.57 during the reporting period[6]. Other Information - Basic earnings per share for the quarter were ¥0.25, marking a 4.17% increase[4]. - The basic and diluted earnings per share for Q1 2024 were both 0.25 RMB, compared to 0.24 RMB in Q1 2023, reflecting an increase of approximately 4.17%[19]. - The weighted average return on equity was 3.34%, a decrease of 0.17 percentage points from the previous year[4]. - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided content[17]. - The company has not indicated any new product launches or significant market expansion strategies in the current report[11].